Please read this leaflet carefully before you start using TRELEGY ELLIPTA. This leaflet answers some common questions about TRELEGY ELLIPTA. It does not contain all the available information.
European regulators have refused to back GlaxoSmithKline’s daily triple therapy Trelegy Ellipta for asthma, denying a label extension because there was no evidence to show a reduction of flare-ups.
Preview: FC Twente Women vs. Chelsea - prediction, team news, lineups Preview: Shrewsbury vs. Exeter - prediction, team news, lineups Preview: Philadelphia 76ers vs. Brooklyn Nets - prediction ...